Beth Israel Deaconess Medical Center, Inc.

The Broad Institute, Inc.

Robert Flaumenhaft

Jeffrey I Zwicker

Bruce Furie

Chris Dockendorff

Jack Davis Stopa

Benito Munoz

Sivaraman Dandapani

Partha Pratim Nag

Jun Pu

Tatiana Pilyugina

Lawrence MacPherson

David Barrios

Secil Koseoglu

Disclosed are compositions and methods for treating sickle cell disease. Also disclosed are methods of treating sickle cell disease comprising administering to a subject in need thereof an effective amount of isoquercetin, vitamin B3, vitamin C, and optionally folic acid and wherein the effective amount is sufficient to halt progression of one or more of the symptoms of sickle cell disease.

Method for treating sickle cell disease using quercetin-containing compositions

The present invention relates to methods for reducing soluble P-selectin and major thrombotic events in cancer patients.

Compositions and methods for reducing major thrombotic events in cancer patients

In some aspects, the disclosure relates to compositions and methods for detecting phosphorylation of dynamin-related protein 1 (Dip1) at position Ser-616. In some embodiments, methods described by the disclosure are useful for detecting antiplatelet agent sensitivity in a subject. In some embodiments, methods described by the disclosure are useful for detecting if a subject has been previously exposed to an antiplatelet agent.

Compositions and methods for evaluation of antiplatelet drug sensitivity

The invention provides compounds of formula (I) that inhibit PDI, for use in methods to treat or prevent a disease or condition in a subject that would benefit by inhibition of PDI. Formula (I) 

Compounds for use in methods for treating diseases or conditions mediated by protein disulfide isomerase

The invention relates to the use of a compound of Formula I for the treatment of protease-activated receptor mediated diseases by the administration of a compound of Formula I or a prodrug or metabolite thereof. 

Compounds and methods for treating diseases mediated by protease activated receptors

The invention provides methods and compositions for reducing platelet activation, platelet aggregation and thrombosis. The invention further provides compositions and methods for treating or preventing diseases or disorders in which the pathology of the disease or disorder involves one or more of platelet activation, platelet aggregation and thrombus formation. The invention additionally relates to the use of protein palmitoylation inhibitors for the reduction of platelet activation, platelet aggregation and thrombosis, as well as to the use of protein palmitoylation as a target for the identification of inhibitors of platelet activation, platelet aggregation and thrombosis.

Growing community of inventors

Newton, MA, United States of America

Robert Flaumenhaft